Eric Schilling, DO
Critical Care Medicine · St Petersburg, FLNPI 1740509348
Payments from drug & device makers
Across 381 payments — averaging $312.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$105K
- Intuitive Surgical$6K
- Pulmonx Corporation$2K
- GSK$1K
- AstraZeneca$993
- Actelion Pharmaceuticals US, Inc.$631
- plus $4K from 33 others
What the payments were for
- Travel & lodging$3,36824%
- Food & beverage$7,65454%
- Education$3,05122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 33 | $105,030 |
| Intuitive Surgical | 19 | $5,812 |
| Pulmonx Corporation | 10 | $1,516 |
| GSK | 73 | $1,180 |
| AstraZeneca(2 entities) | 44 | $993 |
| Actelion Pharmaceuticals US, Inc. | 29 | $631 |
| Insmed, Inc. | 22 | $453 |
| Boehringer Ingelheim | 24 | $435 |
| Regeneron Healthcare Solutions, Inc. | 12 | $296 |
| Harmony Biosciences LLC | 8 | $248 |
| Shionogi Inc | 11 | $205 |
| Jazz Pharmaceuticals Inc. | 9 | $187 |
| Amgen | 9 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $157 |
| Sanofi | 6 | $152 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Sanofi US Services Inc. | 1 | $121 |
| AbbVie(2 entities) | 5 | $119 |
| Grifols USA, LLC | 4 | $103 |
| Gilead | 4 | $87 |
| Mylan Specialty L.p. | 4 | $85 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Bayer | 4 | $71 |
| Baxter Healthcare | 4 | $69 |
| Johnson & Johnson | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 5 | $65 |
| Inspire Medical Systems, Inc. | 2 | $54 |
| Electromed, Inc. | 4 | $50 |
| Portola Pharmaceuticals, LLC | 3 | $48 |
| Ambu Inc. | 3 | $45 |
| Pfizer | 3 | $45 |
| Verona Pharma, Inc. | 2 | $45 |
| Merck | 3 | $43 |
| Philips North America LLC | 1 | $28 |
| Vapotherm Inc | 1 | $28 |
| Novartis | 2 | $28 |
| Genentech USA, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Nuwellis, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,451
- ZEPHYR ENDOBRONCHIAL VALVE$1,392
- IMFINZI$125
- TEZSPIRE$122
- OPDIVO$121
- AYVAKIT$121
How this compares
$118,917 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $80,798 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $19,226 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $17,993 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,692 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,619 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,941 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,162 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,447 |
| Montelukast Sodium | 45 | $561 |
| Fluticasone Propionate | 14 | $366 |
| Trazodone Hcl | 21 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,180 | $118,016161 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $993 | $13,63326 claims |
| Boehringer IngelheimSpiriva Respimat | $435 | $12,27918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in St Petersburg
- Warren AbelSt Petersburg$448K
- Hudman HooSt Petersburg$191K
- Vinny SamuelSt Petersburg$178K
- Ala AhmadSt Petersburg$177K
- Jeffrey LevyHollywood$19M
- Ahmad AswadMiami$6.6M
- George DuvallVero Beach$6M
- Fortune AlabiKissimmee$3.2M
- Carlos VacaMiami$3M
- Debabrata BandyopadhyayTampa$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.